Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

601. Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis

Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Catalan Agency for Health Technology Assessment and Research Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Catalan Agency for Health Technology Assessment and Research. Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). Technical Assessment. 2004

2004 Health Technology Assessment (HTA) Database.

602. Drotrecogin alfa (activated) for severe sepsis

Drotrecogin alfa (activated) for severe sepsis Drotrecogin alfa (activated) for severe sepsis Drotrecogin alfa (activated) for severe sepsis National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Drotrecogin alfa (activated) for severe sepsis. National Institute for Clinical (...) Excellence (NICE). Technology Appraisal Guidance 84. 2004 Authors' objectives To provide guidance on the use of drotrecogin alfa (activated) for severe sepsis. Authors' conclusions Guidance 1.1 Drotrecogin alfa (activated) is recommended for use in adult patients who have severe sepsis that has resulted in multiple organ failure (that is, two or more major organs have failed) and who are being provided with optimum intensive care support. 1.2 The use of drotrecogin alfa (activated) should only

2004 Health Technology Assessment (HTA) Database.

603. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Full Text available with Trip Pro

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. To compare beta lactam monotherapy with beta lactam-aminoglycoside combination therapy for severe infections.Medline, Embase, Lilacs, Cochrane Library, and conference proceedings, to 2003; references of included studies; contact with all authors. No restrictions, such as language, year of publication, or publication (...) aeruginosa infections (426 patients). There was no difference in the rate of development of resistance. Nephrotoxicity was significantly more common with combination therapy (0.36, 0.28 to 0.47). Heterogeneity was not significant for these comparisons.In the treatment of sepsis the addition of an aminoglycoside to beta lactams should be discouraged. Fatality remains unchanged, while the risk for adverse events is increased.

2004 BMJ

604. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2004 PedsCCM Evidence-Based Journal Club

605. Corticosteroids for treating severe sepsis and septic shock. (Abstract)

Corticosteroids for treating severe sepsis and septic shock. Sepsis may be complicated by impaired corticosteroid production. Giving corticosteroids could potentially benefit patients.To examine the effects of corticosteroids on death at one month in patients with severe sepsis and septic shock.We searched the Cochrane Infectious Diseases Group's trial register (August 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2003), MEDLINE (August 2003 (...) ), EMBASE (August 2003), LILACS (August 2003), reference lists of articles, and also contacted trial authors.Randomized and quasi-randomized controlled trials of corticosteroids versus placebo or supportive treatment in severe sepsis and septic shock.Two pairs of reviewers agreed the eligibility of trials. One reviewer extracted data, which was checked by the other reviewers and the primary author of the paper whenever possible. We obtained some missing data from the trial authors. We assessed trial

2004 Cochrane

606. The epidemiology of sepsis in the United States from 1979 through 2000. Full Text available with Trip Pro

The epidemiology of sepsis in the United States from 1979 through 2000. Sepsis represents a substantial health care burden, and there is limited epidemiologic information about the demography of sepsis or about the temporal changes in its incidence and outcome. We investigated the epidemiology of sepsis in the United States, with specific examination of race and sex, causative organisms, the disposition of patients, and the incidence and outcome.We analyzed the occurrence of sepsis from 1979 (...) through 2000 using a nationally representative sample of all nonfederal acute care hospitals in the United States. Data on new cases were obtained from hospital discharge records coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification.Review of discharge data on approximately 750 million hospitalizations in the United States over the 22-year period identified 10,319,418 cases of sepsis. Sepsis was more common among men than among women (mean annual

2003 NEJM

607. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? (Abstract)

A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Despite the advances in supportive care and the availability of potent antimicrobial agents, mortality from sepsis, a leading cause of death in intensive care units, has not improved. Over the last decade, clinical trials with numerous adjunctive therapies, including antiendotoxin antibodies and inhibitors of the inflammatory response, have yielded disappointing results. Recently, treatment with recombinant (...) human activated protein C reduced mortality 6% compared with controls. Given the likelihood that many processes in the complex pathophysiology of sepsis are simultaneously activated, it is unlikely that therapy directed at any one of them, as has been done in the past, will dramatically improve survival. Rather, a combination of therapies directed at many arms of the septic process, much like the strategy used for cancer and HIV infection, is required. Given the likelihood that sepsis represents

2003 Annals of Internal Medicine

608. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Neilson A R, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was drotrecogin alpha (activated) (DAA) for the treatment of severe sepsis. DAA was given in 5mg vials based on a 12 hourly dosage. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised both the whole

2003 NHS Economic Evaluation Database.

609. Evaluation of drotrecogin alpha in adult patients with severe sepsis

Evaluation of drotrecogin alpha in adult patients with severe sepsis Evaluation of drotrecogin alpha in adult patients with severe sepsis Evaluation of drotrecogin alpha in adult patients with severe sepsis Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Evaluation of drotrecogin alpha in adult patients with severe sepsis. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives This study aims to summarise the available evidence on the use of drotrecogin alpha in adult patients with severe sepsis. Authors' conclusions The benefit of drotrecogin alpha was established within the context of state-of-the-art

2003 Health Technology Assessment (HTA) Database.

610. Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert)

Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Swedish Council on Technology Assessment in Health Care. Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2003 Authors' objectives This review aims to assess the available evidence on drotrecogin alfa (Xigris(R)) for severe sepsis. Authors' conclusions Currently there is moderate scientific evidence that show positive effects of drotrecogin alfa on survival in patients with severe sepsis

2003 Health Technology Assessment (HTA) Database.

611. Beyond the complete blood cell count and C-reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis

Beyond the complete blood cell count and C-reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

612. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Full Text available with Trip Pro

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation.To determine if administration of tifacogin (recombinant TFPI) provides mortality (...) benefit in patients with severe sepsis and elevated international normalized ratio (INR) and to assess tifacogin safety in severe sepsis, including patients with low INR.A randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial conducted from March 21, 2000, through September 27, 2001, in 245 hospitals in 17 countries in North America, Europe, and Israel.The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2

2003 JAMA Controlled trial quality: predicted high

613. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

614. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Fowler R A, Hill-Popper M, Stasinos J, Petrou C (...) , Sanders G D, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of recombinant human activated protein C (drotrecogin alfa) for patients with severe sepsis who were being treated in an intensive care unit (ICU). Four

2003 NHS Economic Evaluation Database.

615. Drotrecogin alfa (Xigris®) for severe sepsis</a>

Drotrecogin alfa (Xigris®) for severe sepsis Drotrecogin alfa (Xigris®) for severe sepsis We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Drotrecogin alfa (Xigris®) for severe sepsis Share: Reading time approx. 5 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version (...) : 1 Technology and target group Sepsis is a life-threatening condition characterized by a systemic inflammatory response to infection. The condition is classified as severe sepsis if at least one vital organ system ceases to function. Septic shock is diagnosed when low arterial blood pressure that does not resolve with adequate fluid resuscitation occurs. Mortality is approximately 20 percent in cases of severe sepsis and 45 percent in cases of septic shock. Drotrecogin alfa (Xigris®) is a new

2003 Swedish Council on Technology Assessement

616. Early enteral immunonutrition in patients with severe sepsis: Results of an interim analysis of a randomized multicentre clinical trial.

Early enteral immunonutrition in patients with severe sepsis: Results of an interim analysis of a randomized multicentre clinical trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2003 PedsCCM Evidence-Based Journal Club

617. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2003 PedsCCM Evidence-Based Journal Club

618. Pentoxifylline for neonatal sepsis. (Abstract)

Pentoxifylline for neonatal sepsis. Although the overall incidence of neonatal sepsis has declined over the past decade, mortality remains high in the pre term infant. The high level of mortality and morbidity from sepsis despite the use of potent anti-microbial agents, and the global emergence of antibiotic resistance, have led to the search for new modalities to boost new born host defences. Pentoxifylline, a xanthine derivative and a phosphodiesterase inhibitor, has been shown to possess (...) sepsis in newborn infants less than 28 days old. Eligible trials were required to report treatment effects on at least one of the following outcomes: all cause mortality during initial hospital stay, neurological development at two years of age or later, length of hospital stay, duration of ventilation via endotracheal intubation, chronic lung disease in survivors, periventricular leukomalacia, necrotising enterocolitis, or adverse events.Two reviewers independently abstracted information

2003 Cochrane

619. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. (Abstract)

Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Neonatal sepsis causes significant neonatal mortality and morbidity. Neonates, especially preterm infants, have an immaturity of granulopoeisis and have a limited capacity for progenitor cell proliferation. This results in the frequent occurrence of neutropaenia in septic neonates. Neutropaenic septic neonates have a higher mortality than neonates who are septic but not neutropaenic. Transfusion (...) of granulocytes to septic neutropaenic neonates, therefore, may help reduce mortality and morbidity.The primary objective of this review was to determine the efficacy and safety of granulocyte preparations (granulocyte and buffy coat transfusions) as adjuncts to antibiotics for the treatment of confirmed or suspected sepsis in neonates with neutropaenia in reducing all-cause mortality during hospital stay and adverse neurological outcome at a year of age or later. Secondary objectives were to determine

2003 Cochrane

620. An economic evaluation of activated protein C treatment for severe sepsis. (Abstract)

An economic evaluation of activated protein C treatment for severe sepsis. Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis. A post hoc reanalysis by the Food and Drug Administration (FDA) of data from this study suggested that the reduction in mortality was restricted to patients with Acute Physiology and Chronic Health Evaluation (APACHE II (...) ) scores of 25 or more.We estimated the cost effectiveness of activated protein C as compared with conventional care for patients with severe sepsis. We performed an economic analysis involving all patients, as well as analyses of subgroups defined according to age and severity of illness. The probabilities of transition between clinical states and the estimates of resource use were derived from a population-based cohort of patients with severe sepsis. We used data on the effectiveness of activated

2002 NEJM